Dexcom, Inc. a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that the U.S. Food and Drug Administration (FDA) has approved the Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System. With wireless Bluetooth® technology built into the device transmitter, the G5 Mobile CGM System is the first and only fully mobile CGM system approved by the FDA for both adults and children as young as 2 years of age that sends glucose data directly to a smartphone, freeing users from the need to carry a separate receiver. The new transmitter securely sends vital glucose information directly to an app on iOS-enabled devices for real-time diabetes management. Android applications will follow early next year. Like its predecessor, the G4 PLATINUM CGM with Share, users can also select up to five designated recipients, or “followers”. These followers can remotely monitor a patient’s glucose information and receive alert notifications from almost anywhere.
About the Dexcom U.S. G5 Mobile Launch
- The G5 Mobile system is anticipated to begin shipping in late September 2015.
- All purchasers of a G4 Platinum with Share system from August 1, 2015, until the G5 Mobile system is shipped, will be eligible to receive a no-cost upgrade to the G5 Mobile system.
- There will be a low cost cash upgrade to the G5 Mobile system for those patients who are still under warranty with their existing system.
For more information:
Call Kristen Paulmeyer or Jennifer Mathews
Diabetes Center of the Midlands
402-399-8444 ext. 2
Categorised in: Education
This post was written by Nabil Molai